Wat is de prijs voor Liminal BioSciences Inc. (LMNL)

Het prijs van Liminal BioSciences Inc. (LMNL) is $8.50

Wat is de marktkapitalisatie voor Liminal BioSciences Inc. (LMNL)

Marktkapitalisatie voorLiminal BioSciences Inc. (LMNL) is $719.10K

Liminal BioSciences Inc. (LMNL) K/B-verhouding

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.

Jaar	P/B-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/B-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	-	US
Argenx SE ARGX.US	6.3483	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.634	-	BE

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land